Publication Name	World Journal of Meta-Analysis
Manuscript ID	24044
Country	China

Received	2016-01-03 18:05
Peer-Review Started	2016-01-03 19:05
To Make the First Decision	2016-02-29 14:42
Return for Revision	2016-03-03 15:35
Revised	2016-03-14 23:04
Second Decision	2016-04-11 09:07
Accepted by Journal Editor-in-Chief	2016-04-11 18:31
Accepted by Company Editor-in-Chief	2016-04-22 16:22
Articles in Press	2016-04-22 16:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-06-14 14:11
Publish the Manuscript Online	2016-06-16 18:11

ISSN	2308-3840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Meta-Analysis
Article Title	Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Cheng Fang, Cai-Liang Wu, Sha-Sha Liu, Long Ge and Jin-Liang Bai
Funding Agency and Grant Number
Corresponding Author	Jin-Liang Bai, Professor, Department of Urological, First Clinical Medical College of Lanzhou University, No. 1, Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. 541301922@qq.com
Key Words	Prostate cancer; Degarelix; Meta-analysis
Core Tip	This meta-analysis and systematic review aimed to compare the efficacy, safety, and dosage regimens of degarelix for prostate cancer. A total of seven papers from 6 randomized controlled trials were identified, involving 1204 patients. Degarelix was an useful option in the treatment of advanced prostate cancer, and degarelix 240/160 mg regimen was superior to 240/80 mg regimen.
Publish Date	2016-06-16 18:11
Citation	Fang C, Wu CL, Liu SS, Ge L, Bai JL. Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis. World J Meta-Anal 2016; 4(3): 69-76
URL	http://www.wjgnet.com/2308-3840/full/v4/i3/69.htm
DOI	http://dx.doi.org/10.13105/wjma.v4.i3.69

Full Article (PDF)	WJMA-4-69.pdf
Full Article (Word)	WJMA-4-69.doc
Manuscript File	24044-Review.doc
Answering Reviewers	24044-Answering reviewers.pdf
Audio Core Tip	24044-Audio core tip.mp3
Biostatistics Review Certificate	24044-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	24044-Conflict-of-interest statement.pdf
Copyright License Agreement	24044-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	24044-Language certificate.pdf
Peer-review Report	24044-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	24044-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	24044-Scientific misconduct check.pdf
Scientific Editor Work List	24044-Scientific editor work list.pdf